olaratumab
abagovomab
brolucizumab
pozelimab
solitomab
toripalimab
gevokizumab
zenocutuzumab
antipolyvalent
heterophile
atezolizumab
antigenically
antinucleosome
antisynthetase
heterophilic
multiantigenic
polytypic
polyvalent
guselkumab
heteroclitic
agonistic monoclonal antibody
brentuximab
immunoglobin
paratope
allotope
tucotuzumab
sonepcizumab
cytotoxic reaction
elotuzumab
immunosorbent
bivatuzumab
oportuzumab monatox
cross-reactivity
immunoprobe
polyantibody
alacizumab
amlitelimab
immunospecific
polyantigenic
intetumumab
crossreactive
immunorepressive
anti-nuclear factor
microlymphocytotoxicity
antimonoclonal